Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cassava Sciences, Inc.

https://www.cassavasciences.com/

Latest From Cassava Sciences, Inc.

Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Leadership Launches

Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners

AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.

Deal Watch Business Strategies

Keeping Track: TGT’s Ukoniq Is Latest PI3K Inhibitor To Fall; GSK’s Daprodustat, Aeglea’s Pegzilarginase Headline Submissions

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Are Investors ‘Skeptical’ Of Fresenius Kabi’s €495m mAbxience Acquisition?

Fresenius Kabi’s proposed agreement to acquire a majority 55% stake in biosimilars firm mAbxience has been put under the microscope by one analyst, amid setbacks that have stymied the return on investment for Kabi’s nascent biosimilars unit.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Pain Therapeutics, Inc.
UsernamePublicRestriction

Register